Search published articles
Showing 4 results for Monoclonal Antibody
Volume 7, Issue 1 (1-2005)
Abstract
Two strains -425 and Y87/47- of Alfalfa mosaic virus (AMV) were propagated in and purified from Nicotiana tabacum cv. Samsun NN. Thirty-three AMV specific monoclonal antibodies (MAbs) from two fusions were raised against strain 425. These antibodies were of isotypes IgG1 and IgM. MAbs recognised three types of epitope. Group I did not react with the virus particle surface or viral coat protein of two strains in PTA-ELISA, but they reacted with a 30-kDa structural coat protein of AMV by immunoblot analysis only and were able to recognise cryptotopes. Group II reacted with metatopes of both strains in PTA-ELISA. Group III reacted with a 30-kDa structural coat protein of AMV by immunoblot analysis and in PTA-ELISA for the Y87/47 strain only. Immunoblocking experiments in which suspensions of purified AMV and MAb were offered between parafilm membranes for acquisition by Myzus persicae revealed that MAb-2 was effective in blocking (inhibiting) transmission. This result suggests that the epitope which was localised by MAb-2 plays a role in the aphid transmission of AMV.
B. Onagh, S. Hasannia, F. Heidari,
Volume 10, Issue 3 (9-2019)
Abstract
Bone morphogenetic proteins (BMPs) belong to the superfamily transforming growth factor-beta. These molecules play a role in fetal development and differentiation of different cells. In this regard, two homodimer molecules BMP-2 and BMP-7 play an important role in the formation of ectopic bone So that two types of recombinant form are available for ectopic use. After binding of the homodimer BMP-2 to its receptor at the cell surface, the accumulation of homodimers of type I and II receptors results in a biological response within the cell. Despite the existence of recombinant types of BMP-2 and BMP-7 due to the dangers of their use, the strategy of using monoclonal antibodies to trap endogenous types is still a priority in research programs. Instead of using monoclonal antibodies, the alternative method is to use the natural receptors of the ligand in the body. In this regard, due to the proper Kd binding of the ectodomain component of the receptor II of the BMP molecule in this project, the expression and purification of this part were attempted to trap BMP-2 endogenous. The protein component of the type II receptor ectodomain was expressed and purified by the bacterial host, which, by evaluating CD, of this recombinant protein showed a similar structure to that of the natural type. Also, its binding to the BMP-2 ligand with ELISA was evaluated and then calculated as Kd. Based on the results, the type II receptor ectodomain can be connected to the BMP-2 with a suitable binding property at the nM concentration, and in subsequent studies, it can be used as an alternative to a monoclonal antibody to Trap endogenous BMP molecules.
Volume 16, Issue 4 (2-2014)
Abstract
Objective: The study of physiological changes in recombinant cell lines provides useful information to improve production performance. In this study, we investigate the effects of an anti-CD33 chimeric IgG4 expression on Sp2.0 cell growth.
Methods: Variable region genes of light and heavy chains of monoclonal antibody produced by M195 were cloned in pFUSE-CLIg-hk and pFUSE-CHIg-hG4 expression vectors, respectively. Transfection of recombinant plasmids into Sp2.0 cell lines was performed using lipofectamine in two steps. Positive transformant cells were isolated and subjected to PCR, RT-PCR and Western blot analysis to confirm the integration of gene cassettes and the expression of recombinant IgG4.
To assess the growth parameters, recombinant and parent Sp2.0 cell lines were seeded at a density of 1×105 cells/ml in duplicate into 12-well plates. For nine days, culture plates were sampled daily and viable cell count and viability determined.
Results: The results of PCR, RT-PCR and Western blot analyses confirmed the generation of stable producer cell lines. In recombinant cells, the maximum cell density decreased by 46%. However, it was observed that IgG4 expression had no effect on cell viability of these transfectants.
Conclusion: Our results showed that the expression of recombinant IgG4 can change growth parameters in Sp2.0 cell lines that express the pFUSE-CHIg-hG4-pFUSE-CLIg-hk construct.
Volume 23, Issue 0 (3-2021)
Abstract
The new coronavirus was firstly identified in the late December 2019 that causes severe respiratory and other organ complications in Covid-19 patients. Although many attempts have been employed to introduce and provide effective medications against this infection, there is still no definitive treatment for the infection. However some agents have shown promising effects in patients and some others are in preliminary or clinical studies. Monoclonal antibodies are of great interest in the treatment of Covid-19, but despite the fact that more than 120 clinical trials have been performed or are being completed; only tocilizumab has shown promising results and is sometimes used in therapeutic protocols. In this review, therapeutic monoclonal antibodies against Covid-19 that are currently in phase 3 or higher clinical trial have been discussed.
